Ocular gene therapy: current progress and future prospects

Trends in Molecular Medicine

Volumn 15, Issue 1, 2009, Pages 23-31

  Colella, Pasqualina ^a,b   Cotugno, Gabriella ^a,c   Auricchio, Alberto ^a,d  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b OPEN UNIVERSITY   (United Kingdom)

^c European School of Molecular Medicine SEMM   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EYE PROTEIN; HERPES VIRUS THYMIDINE KINASE; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; RETINAL PIGMENT EPITHELIUM SPECIFIC PROTEIN 65; SMALL INTERFERING RNA; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANTERIOR EYE SEGMENT; BLINDNESS; CLINICAL TRIAL; COLOR BLINDNESS; ELECTRON MICROSCOPY; EYE DISEASE; GENE THERAPY; GENE TRANSFER; HUMAN; IN VIVO GENE TRANSFER; LEBER CONGENITAL AMAUROSIS; NONHUMAN; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINOBLASTOMA; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; EYE DISEASES; GENE THERAPY; HUMANS;

ANIMALIA;

EID: 58149484922     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.11.003     Document Type: Review

References (89)

1. Dalke C., and Graw J. Mouse mutants as models for congenital retinal disorders. Exp. Eye Res. 81 (2005) 503-512
2. Dejneka N.S., et al. Gene therapy and animal models for retinal disease. Dev. Ophthalmol. 37 (2003) 188-198
3. Bainbridge J.W., et al. Gene therapy progress and prospects: the eye. Gene Ther. 13 (2006) 1191-1197
4. Andrieu-Soler C., et al. Ocular gene therapy: a review of nonviral strategies. Mol. Vis. 12 (2006) 1334-1347
5. Allocca M., et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J. Virol. 81 (2007) 11372-11380
6. Lebherz C., et al. Novel AAV serotypes for improved ocular gene transfer. J. Gene Med. 10 (2008) 375-382
7. Lai Y.K., et al. Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 9 (2002) 804-813
8. Allocca M., et al. AAV-mediated gene transfer for retinal diseases. Expert Opin. Biol. Ther. 6 (2006) 1279-1294
9. Hacein-Bey-Abina S., et al. Insertional oncogenesis in four patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118 (2008) 3132-3142
10. Surace E.M., and Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res. 48 (2008) 353-359
11. Surace E.M., and Auricchio A. Adeno-associated viral vectors for retinal gene transfer. Prog. Retin. Eye Res. 22 (2003) 705-719
12. Kong J., et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 15 (2008) 1311-1320
13. Williams M.L., et al. Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. PLoS Med. 3 (2006) e201
14. Miyoshi H., et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10319-10323
15. Balaggan K.S., et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J. Gene Med. 8 (2006) 275-285
16. Mori K., et al. Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1610-1615
17. Budenz D.L., et al. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 36 (1995) 2211-2215
18. Gehlbach P., et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum. Gene Ther. 14 (2003) 129-141
19. Tsubota K., et al. Adenovirus-mediated gene transfer to the ocular surface epithelium. Exp. Eye Res. 67 (1998) 531-538
20. Reichel M.B., et al. Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Ther. 5 (1998) 1038-1046
21. Chevez-Barrios P., et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J. Clin. Oncol. 23 (2005) 7927-7935
22. Lamartina S., et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J. Gene Med. 9 (2007) 862-874
23. Kreppel F., et al. Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1965-1970
24. Yang G.S., et al. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J. Virol. 76 (2002) 7651-7660
25. Weber M., et al. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol. Ther. 7 (2003) 774-781
26. Allocca M., et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J. Clin. Invest. 118 (2008) 1955-1964
27. Klausner E.A., et al. Corneal gene therapy. J. Control. Release 124 (2007) 107-133
28. Alexander J.J., and Hauswirth W.W. Adeno-associated viral vectors and the retina. Adv. Exp. Med. Biol. 613 (2008) 121-128
29. Lai C.M., et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12 (2001) 1299-1310
30. Singh N., et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest. Ophthalmol. Vis. Sci. 46 (2005) 1647-1652
31. Kim B., et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165 (2004) 2177-2185
32. Lai C.M., et al. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp. Eye Res. 75 (2002) 625-634
33. Li T., and Davidson B.L. Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7700-7704
34. Kamata Y., et al. Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. Mol. Ther. 4 (2001) 307-312
35. Michaelides M., et al. The genetics of inherited macular dystrophies. J. Med. Genet. 40 (2003) 641-650
36. Michaelides M., et al. The cone dysfunction syndromes. Br. J. Ophthalmol. 88 (2004) 291-297
37. Hartong D.T., et al. Retinitis pigmentosa. Lancet 368 (2006) 1795-1809
38. Chang B., et al. Cone photoreceptor function loss-3, a novel mouse model of achromatopsia due to a mutation in Gnat2. Invest. Ophthalmol. Vis. Sci. 47 (2006) 5017-5021
39. Alexander J.J., et al. Restoration of cone vision in a mouse model of achromatopsia. Nat. Med. 13 (2007) 685-687
40. Komaromy A.M., et al. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. Gene Ther. 15 (2008) 1073
41. Molday R.S. ATP-binding cassette transporter ABCA4: molecular properties and role in vision and macular degeneration. J. Bioenerg. Biomembr. 39 (2007) 507-517
42. Weng J., et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 98 (1999) 13-23
43. +/- mice: implications for involvement of ABCR in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1685-1690
44. Saishin Y., et al. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum. Gene Ther. 16 (2005) 473-478
45. Mori K., et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1994-2000
46. Mori K., et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2428-2434
47. Auricchio A., et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol. Ther. 6 (2002) 490-494
48. Campochiaro P.A., et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum. Gene Ther. 17 (2006) 167-176
49. Clackson T. Regulated gene expression systems. Gene Ther. 7 (2000) 120-125
50. Stieger K., et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol. Ther. 13 (2006) 967-975
51. Smith J.R., et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum. Gene Ther. 16 (2005) 1037-1046
52. Lebherz C., et al. Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum. Gene Ther. 16 (2005) 178-186
53. Bainbridge J.W., et al. Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization. Gene Ther. 10 (2003) 1049-1054
54. Silva G.A.C., et al. Externally regulated AAV-mediated delivery of PEDF ameliorates the OIR phenotype. ARVO 2008 Annual Meeting: 2008 April 27-May 1; Ft Lauderdale, FL (2008), Association for Research in Vision and Ophthalmology, Inc.
55. Yokoi K., et al. Gene transfer of an engineered zinc finger protein enhances the anti-angiogenic defense system. Mol. Ther. 15 (2007) 1917-1923
56. Campochiaro P.A. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther. 13 (2006) 559-562
57. Reich S.J., et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9 (2003) 210-216
58. Cashman S.M., et al. Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest. Ophthalmol. Vis. Sci. 47 (2006) 3496-3504
59. Cremers F.P., et al. Molecular genetics of Leber congenital amaurosis. Hum. Mol. Genet. 11 (2002) 1169-1176
60. Ahmed E., and Loewenstein J. Leber congenital amaurosis: disease, genetics and therapy. Semin. Ophthalmol. 23 (2008) 39-43
61. Koenekoop R.K. RPGRIP1 is mutated in Leber congenital amaurosis: a mini-review. Ophthalmic Genet. 26 (2005) 175-179
62. Batten M.L., et al. Pharmacological and rAAV gene therapy rescue of visual functions in a blind mouse model of Leber congenital amaurosis. PLoS Med. 2 (2005) e333
63. Pang J.J., et al. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol. Ther. 13 (2006) 565-572
64. Dejneka N.S., et al. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol. Ther. 9 (2004) 182-188
65. Acland G.M., et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28 (2001) 92-95
66. Narfstrom K., et al. Functional and structural evaluation after AAV.RPE65 gene transfer in the canine model of Leber's congenital amaurosis. Adv. Exp. Med. Biol. 533 (2003) 423-430
67. Bennicelli J., et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol. Ther. 16 (2008) 458-465
68. Le Meur G., et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 14 (2007) 292-303
69. Acland G.M., et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol. Ther. 12 (2005) 1072-1082
70. -/- dogs produces long-term visual improvement. J. Hered. 94 (2003) 31-37
71. Jacobson S.G., et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum. Gene Ther. 17 (2006) 845-858
72. Buch P.K., et al. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther. 15 (2008) 849-857
73. Bainbridge J.W., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008) 2231-2239
74. Maguire A.M., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008) 2240-2248
75. Hauswirth W., et al. Phase I trial of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results. Hum. Gene Ther. (2008). http://www.liebertonline.com/loi/hum 10.1089/hgt.2008.107
76. Simonelli F., et al. Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest. Ophthalmol. Vis. Sci. 48 (2007) 4284-4290
77. Cideciyan A.V., et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 15112-15117
78. Smith A.J., et al. AAV-mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol. Ther. 8 (2003) 188-195
79. Tschernutter M., et al. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther. 12 (2005) 694-701
80. Hashimoto T., et al. Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B. Gene Ther. 14 (2007) 584-594
81. Zeng Y., et al. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest. Ophthalmol. Vis. Sci. 45 (2004) 3279-3285
82. Min S.H., et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol. Ther. 12 (2005) 644-651
83. Janssen A., et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol. Ther. 16 (2008) 1010-1017
84. Martin K.R., et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4357-4365
85. Tsai J.C., et al. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr. Eye Res. 30 (2005) 1025-1031
86. Shevtsova Z., et al. Potentiation of in vivo neuroprotection by BclX(L) and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons. Gene Ther. 13 (2006) 1569-1578
87. Leaver S.G., et al. AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells. Gene Ther. 13 (2006) 1328-1341
88. Buch P.K., et al. In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. Mol. Ther. 14 (2006) 700-709
89. Leonard K.C., et al. XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One 2 (2007) e314